Skip to main content

Market Overview

Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder

Share:
Akari Therapeutics' Nomacopan Secures Expediated Review Tag For Blistering Skin Disorder
  • The FDA has granted Fast Track designation to Akari Therapeutics Plc's (NASDAQ: AKTX) nomacopan to treat patients with moderate and severe Bullous Pemphigoid (BP).
  • Nomacopan has also been granted orphan drug designation for nomacopan to treat BP by the FDA and the European Medicines Agency (EMA).
  • Fast track is a process designed to facilitate the development and expedite the review of drugs.
  • BP is a severe orphan autoimmune inflammatory blistering skin disease wherein both terminal complement activation (via complement component C5), and the lipid mediator leukotriene B4 (LTB4) have a central role in driving the disease.
  • Akari's lead drug candidate, Nomacopan, is a C5 complement inhibitor that independently and specifically binds to and inhibits leukotriene B4 (LTB4) activity.
  • Price Action: AKTX shares are up 2.13% at $2.39 during the market trading session on the last check Wednesday.
 

Related Articles (AKTX)

View Comments and Join the Discussion!

Posted-In: Briefs Fast Track DesignationBiotech News Penny Stocks Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com